Nothing Special   »   [go: up one dir, main page]

Doores, 2015 - Google Patents

The HIV glycan shield as a target for broadly neutralizing antibodies

Doores, 2015

View PDF @Full View
Document ID
4667120147048890469
Author
Doores K
Publication year
Publication venue
The FEBS journal

External Links

Snippet

The HIV envelope glycoprotein (Env) is the sole target for HIV broadly neutralizing antibodies (bnAbs). HIV Env is one of the most heavily glycosylated proteins known, with approximately half of its mass consisting of host‐derived N‐linked glycans. The high density …
Continue reading at febs.onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus

Similar Documents

Publication Publication Date Title
Doores The HIV glycan shield as a target for broadly neutralizing antibodies
Doores et al. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16
Struwe et al. Site-specific glycosylation of virion-derived HIV-1 Env is mimicked by a soluble trimeric immunogen
Ringe et al. Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes
Behrens et al. Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein
Stewart-Jones et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G
Binley et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
Crispin et al. Structure and immune recognition of the HIV glycan shield
Behrens et al. Structural principles controlling HIV envelope glycosylation
Go et al. Glycosylation benchmark profile for HIV-1 envelope glycoprotein production based on eleven Env trimers
Seabright et al. Protein and glycan mimicry in HIV vaccine design
Crooks et al. Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected
Go et al. Glycosylation site-specific analysis of hiv envelope proteins (jr-fl and con-s) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopesʼ accessibility
Doores et al. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
Ringe et al. Influences on the design and purification of soluble, recombinant native-like HIV-1 envelope glycoprotein trimers
Crispin et al. Targeting host-derived glycans on enveloped viruses for antibody-based vaccine design
Go et al. Comparative analysis of the glycosylation profiles of membrane-anchored HIV-1 envelope glycoprotein trimers and soluble gp140
Pritchard et al. Cell-and protein-directed glycosylation of native cleaved HIV-1 envelope
Dey et al. cGMP production and analysis of BG505 SOSIP. 664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate
EP2765138B1 (en) HIV-1 envelope glycoprotein
Ringe et al. Reducing V3 antigenicity and immunogenicity on soluble, native-like HIV-1 Env SOSIP trimers
Go et al. Glycosylation site-specific analysis of clade C HIV-1 envelope proteins
Coss et al. HIV-1 glycan density drives the persistence of the mannose patch within an infected individual
Shivatare et al. Unprecedented role of hybrid N-glycans as ligands for HIV-1 broadly neutralizing antibodies
Leaman et al. Increased functional stability and homogeneity of viral envelope spikes through directed evolution